Stock Report

Divi's Laboratories Reports Strong Q1 FY27 Results: Consolidated PAT Soars 65% YoY to ₹902 Crore

Posted On : 2026-08-01 14:47:18( TIMEZONE : IST )

Active Pharmaceutical Ingredients (API) giant Divi's Laboratories Limited (BSE: 532454 | NSE: DIVISLAB | CIN: L24110TG1990PLC011535) has released its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026 (Q1 FY27).

Driven by expanded demand across its API synthesis and custom manufacturing businesses, the company delivered robust double-digit top-line growth and a significant expansion in profitability.

Executive Summary & Financial Highlights

Consolidated Performance (Q1 FY27 vs. Q1 FY26)

Total Revenue from Operations: Reached ₹3,080 Crore, growing 27.80% YoY compared to ₹2,410 Crore in Q1 FY26, and up 8.79% QoQ from ₹2,831 Crore in Q4 FY26.

Total Income: Advanced to ₹3,144 Crore, reflecting a 24.32% YoY growth over ₹2,529 Crore in Q1 FY26.

Profit Before Tax (PBT): Rose 60.98% YoY to ₹1,180 Crore (vs. ₹733 Crore in Q1 FY26) and increased 22.53% QoQ from ₹963 Crore.

Profit After Tax (PAT): Surged 65.50% YoY to ₹902 Crore (vs. ₹545 Crore in Q1 FY26), up 20.11% QoQ from ₹751 Crore.

Diluted Earnings Per Share (EPS): Increased to ₹33.95 per share (face value ₹2 each), compared to ₹20.49 in Q1 FY26 and ₹28.31 in Q4 FY26.

Standalone Performance (Q1 FY27 vs. Q1 FY26)

Revenue from Operations: Stood at ₹2,974 Crore (vs. ₹2,357 Crore in Q1 FY26).

Total Income: Reached ₹3,037 Crore (vs. ₹2,476 Crore in Q1 FY26).

Profit Before Tax (PBT): Increased 55.96% YoY to ₹1,165 Crore (vs. ₹747 Crore in Q1 FY26).

Profit After Tax (PAT): Rose 59.96% YoY to ₹891 Crore (vs. ₹557 Crore in Q1 FY26).

Basic & Diluted EPS: Stood at ₹33.55 per share (vs. ₹20.95 in Q1 FY26).

Cost Structure & Forex Movements

Expense Breakdown (Consolidated)

Total consolidated expenses for Q1 FY27 stood at ₹1,964 Crore, compared to ₹1,796 Crore in Q1 FY26 and ₹2,023 Crore in Q4 FY26. Key cost components included:

Cost of Materials Consumed: ₹1,503 Crore (vs. ₹1,010 Crore in Q1 FY26).

Changes in Inventories (Finished/WIP): ₹-517 Crore (vs. ₹-54 Crore in Q1 FY26).

Employee Benefits Expense: ₹408 Crore (vs. ₹340 Crore in Q1 FY26).

Depreciation & Amortization: ₹133 Crore (vs. ₹112 Crore in Q1 FY26).

Finance Costs: Kept minimal at ₹6 Crore.

Other Expenses: ₹431 Crore (vs. ₹385 Crore in Q1 FY26).

Foreign Exchange Impact

During the quarter ended June 30, 2026, Divi's Laboratories reported a forex loss of ₹7 Crore (on both standalone and consolidated bases), compared to a forex gain of ₹39 Crore in the corresponding quarter of the previous financial year.

Tax Provision

Total consolidated tax expense for the quarter was ₹278 Crore (comprising current tax of ₹291 Crore and deferred tax credit of ₹13 Crore), representing an effective tax rate of ~23.56%.

Capital Structure

The company's paid-up equity share capital remained constant at ₹53 Crore (consisting of equity shares with a face value of ₹2.00 each), backed by consolidated other equity reserves of ₹16,708 Crore as of the last audited balance sheet.

Shares of Divi's Laboratories Limited was last trading in BSE at Rs. 8056.65 as compared to the previous close of Rs. 7840.50. The total number of shares traded during the day was 51181 in over 7606 trades.

The stock hit an intraday high of Rs. 8087.00 and intraday low of 7841.50. The net turnover during the day was Rs. 410320067.00.